These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19483734)

  • 1. Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer.
    Castañeda CA; Gomez HL
    Nat Rev Clin Oncol; 2009 Jun; 6(6):308-9. PubMed ID: 19483734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
    Finn RS; Press MF; Dering J; Arbushites M; Koehler M; Oliva C; Williams LS; Di Leo A
    J Clin Oncol; 2009 Aug; 27(24):3908-15. PubMed ID: 19620495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.
    Yardley DA; Hart L; Bosserman L; Salleh MN; Waterhouse DM; Hagan MK; Richards P; DeSilvio ML; Mahoney JM; Nagarwala Y
    Breast Cancer Res Treat; 2013 Jan; 137(2):457-64. PubMed ID: 23224144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA; Stein S
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
    Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H
    J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
    Scaltriti M; Chandarlapaty S; Prudkin L; Aura C; Jimenez J; Angelini PD; Sánchez G; Guzman M; Parra JL; Ellis C; Gagnon R; Koehler M; Gomez H; Geyer C; Cameron D; Arribas J; Rosen N; Baselga J
    Clin Cancer Res; 2010 May; 16(9):2688-95. PubMed ID: 20406840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
    Carey LA; Berry DA; Cirrincione CT; Barry WT; Pitcher BN; Harris LN; Ollila DW; Krop IE; Henry NL; Weckstein DJ; Anders CK; Singh B; Hoadley KA; Iglesia M; Cheang MC; Perou CM; Winer EP; Hudis CA
    J Clin Oncol; 2016 Feb; 34(6):542-9. PubMed ID: 26527775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
    Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
    Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
    Di Leo A; Gomez HL; Aziz Z; Zvirbule Z; Bines J; Arbushites MC; Guerrera SF; Koehler M; Oliva C; Stein SH; Williams LS; Dering J; Finn RS; Press MF
    J Clin Oncol; 2008 Dec; 26(34):5544-52. PubMed ID: 18955454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.
    Jagiello-Gruszfeld A; Tjulandin S; Dobrovolskaya N; Manikhas A; Pienkowski T; DeSilvio M; Ridderheim M; Abbey R
    Oncology; 2010; 79(1-2):129-35. PubMed ID: 21088439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer.
    Downey L; Livingston RB; Koehler M; Arbushites M; Williams L; Santiago A; Guzman R; Villalobos I; Di Leo A; Press MF
    Clin Cancer Res; 2010 Feb; 16(4):1281-8. PubMed ID: 20145176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.
    Inoue K; Kuroi K; Shimizu S; Rai Y; Aogi K; Masuda N; Nakayama T; Iwata H; Nishimura Y; Armour A; Sasaki Y
    Int J Clin Oncol; 2015 Dec; 20(6):1102-9. PubMed ID: 25967286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review.
    Mendes D; Alves C; Afonso N; Cardoso F; Passos-Coelho JL; Costa L; Andrade S; Batel-Marques F
    Breast Cancer Res; 2015 Nov; 17():140. PubMed ID: 26578067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial.
    Masuda N; Toi M; Yamamoto N; Iwata H; Kuroi K; Bando H; Ohtani S; Takano T; Inoue K; Yanagita Y; Kasai H; Morita S; Sakurai T; Ohno S
    Breast Cancer; 2018 Jul; 25(4):407-415. PubMed ID: 29445928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
    Hicks M; Macrae ER; Abdel-Rasoul M; Layman R; Friedman S; Querry J; Lustberg M; Ramaswamy B; Mrozek E; Shapiro C; Wesolowski R
    Oncologist; 2015 Apr; 20(4):337-43. PubMed ID: 25732265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
    Dang C; Lin N; Moy B; Come S; Sugarman S; Morris P; Abbruzzi A; Chen C; Steingart R; Patil S; Norton L; Winer E; Hudis C
    J Clin Oncol; 2010 Jun; 28(18):2982-8. PubMed ID: 20479410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
    Kaklamani VG; Siziopikou K; Scholtens D; Lacouture M; Gordon J; Uthe R; Meservey C; Hansen N; Khan SA; Jeruss JS; Bethke K; Cianfrocca M; Rosen S; Von Roenn J; Wayne J; Parimi V; Jovanovic B; Gradishar W
    Breast Cancer Res Treat; 2012 Apr; 132(3):833-42. PubMed ID: 21359953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.